Tech News
← Home  ·  All topics

Novo Nordisk

8 GoKawiil briefs on this topic · RSS for novo nordisk

Novo Nordisk and Eli Lilly present early data linking GLP-1 drugs to slower biological aging clocks

At the ARDD conference at Harvard, Novo Nordisk and Eli Lilly presented preliminary findings suggesting their GLP-1 receptor agonists, including semaglutide, may slow molecular markers of aging. Novo's study of 10,052 participants found proteomic clock differences of about two to three years between drug and placebo groups, with up to a four-year gap on a clock measuring heart-related proteins.

Novo Nordisk and Eli Lilly data suggest GLP-1 drugs slow molecular aging markers

New data from Novo Nordisk and Eli Lilly indicates that GLP-1 medications, the class that includes Ozempic, may slow biological aging as measured by molecular aging clocks. These clocks track chemical changes in cells believed to correlate with the pace of aging.

Research continues into side effects of popular GLP-1 weight-loss drugs

GLP-1 agonist drugs, approved for diabetes, kidney disease and obesity, are being used by a growing share of Americans, with a recent Gallup poll finding 11% currently take one for weight loss, up from 3% in 2024. Beyond common gastrointestinal issues, pancreatitis and gallstones, researchers and lawsuits are examining rarer possible effects including eye nerve damage, plus emerging questions about hair and nail changes.

Eli Lilly, Novo Nordisk cite aging clocks showing GLP-1 drugs slow biological aging

Eli Lilly and Novo Nordisk report that patients on their GLP-1 drugs show slower biological aging according to molecular 'aging clocks' measuring DNA changes and protein levels. Separately, MIT Technology Review named Energy Dome among its 10 Climate Tech Companies to Watch for 2026, citing its system that stores renewable energy using compressed carbon dioxide rather than underground caverns.

Novo Nordisk and Eli Lilly report GLP-1 drugs slow aging clock readings

Novo Nordisk tested blood from over 10,000 trial participants using proteomic clocks and found signs that its weight-loss drug slowed biological aging, including up to a 4-year shift in a clock measuring heart protein age. Eli Lilly ran a smaller study on tirzepatide using epigenetic clocks that track DNA changes, and also found molecular aging appeared to slow in patients taking the drug compared to placebo.

Novo Nordisk outlines growth strategy beyond weight-loss drugs amid Lilly rivalry

Novo Nordisk this week detailed plans to diversify its business beyond its blockbuster obesity and diabetes treatments, according to CNBC reporting. The move comes as the Danish drugmaker faces intensifying competition from Eli Lilly in the weight-loss drug market.

Anthropic confirms it runs a wet-lab for AI-driven biology experiments

Anthropic has confirmed to TechCrunch that it operates a physical biology lab in the Bay Area, where its AI models help design and test experiments in real life. The company says the lab focuses on fundamental biology research rather than drug discovery, and works both internally and with outside partners, building on its April acquisition of stealth biotech startup Coefficient Bio.

Novo Nordisk shortens brand name to 'Novo' in new consumer-facing rebrand

Novo Nordisk, the Danish pharmaceutical company known for Ozempic and Wegovy, is rebranding itself as simply 'Novo' starting this week. The move shifts the company's public identity toward a shorter, more casual name as it markets directly to consumers rather than solely to healthcare providers.